**Table 3:** Organ involvement in patients and clinical findings.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables** | **Survivor**  **n = 30** | **Ex**  **n = 24** | **HR** | **%95CI** | **p** |
| CNS, n (%) |  |  |  |  |  |
| (-) | 29 (96.7) | 15 (62.5) | ref |  |  |
| (+) | 1 (3.3) | 9 (37.5) | 4.56 | 1.93-10.77 | 0.001\* |
| Polyposis coli, n (%) |  |  |  |  |  |
| (-) | 24 (80.0) | 18 (75.0) | ref |  |  |
| (+) | 6 (20.0) | 6 (25.0) | 1.64 | 0.65-4.19 | 0.298 |
| B symptom, n (%) |  |  |  |  |  |
| (-) | 22 (73.3) | - | ref |  |  |
| (+) | 8 (26.7) | 24 (100.0) | 57.26 | 2.10-1560.80 | 0.016\* |
| Bone marrow, n (%) |  |  |  |  |  |
| (-) | 22 (73.3) | 3 (12.5) | ref |  |  |
| (+) | 8 (26.7) | 21 (87.5) | 10.15 | 2.98-34.64 | < 0.001\* |
| Extra-nodal, n (%) |  |  |  |  |  |
| (-) | 24 (80.0) | - | ref |  |  |
| (+) | 6 (20.0) | 24 (100.0) | 90.22 | 3.24-2515.14 | 0.008\* |
| CyclinD1, n (%) |  |  |  |  |  |
| (-) | 7 (23.3) | 1 (4.2) | ref |  |  |
| (+) | 23 (76.7) | 23 (95.8) | 4.82 | 0.65-35.77 | 0.124 |
| Trans11.14, n (%) |  |  |  |  |  |
| (-) | 2 (6.7) | 1 (4.2) | ref |  |  |
| (+) | 16 (53.3) | 9 (37.5) | 1.22 | 0.15-9.66 | 0.854 |
| (?) | 12 (40.0) | 14 (58.3) | 2.03 | 0.27-15.49 | 0.495 |
| SOX11, n (%) |  |  |  |  |  |
| (-) | 2 (6.7) | - | ref |  |  |
| (+) | 6 (20.0) | 5 (20.8) | 1.21 | 0.01-24.47 | 0.928 |
| (?) | 22 (73.3) | 19 (79.2) | 0.83 | 0.01-16.55 | 0.931 |

Categorical variables were shown as number (%).

\*p < 0.05 shows statistical significance.

**Abbreviations:** HR: Hazard ratio, CI: Confidence interval, CNS: Central nervous system.